Veeda Clinical Research has joined OmniComm Systems CRO Preferred Program, and has signed an agreement to run its first study. The Phase I oncology trial will use the TrialMaster EDC suite to manage data collection, submission, and medical coding needs. The CRO program offers a dedicated, hosted environment, sales and marketing support, as well as training.
“We specifically selected TrialMaster due to their experience and expertise in conducting Oncology trials,” said Sharon Jameson, vice president of Global Clinical Operations. “We are also pleased to have OmniComm as a strategic partner and look forward to working with them on mutual projects in the future.”
“We look forward to working with this highly specialized CRO,” said Stephen Johnson, president and chief operating officer of OmniComm Systems. “We have a tremendous amount of oncology experience and our TrialMaster solution is especially suited for these types of complex studies.”